Biogen (BIIB)
(Delayed Data from NSDQ)
$204.76 USD
-0.06 (-0.03%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $204.61 -0.15 (-0.07%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Price, Consensus and EPS Surprise
BIIB 204.76 -0.06(-0.03%)
Will BIIB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BIIB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BIIB
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term
BIIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Do Options Traders Know Something About Biogen (BIIB) Stock We Don't?
Will Ionis' (IONS) Wholly-Owned Drugs Drive Future Growth?
Is Eli Lilly (LLY) a Buy Post Stellar Q2 Earnings & Raised View?
Other News for BIIB
Viridian Therapeutics: Key Inflection Points Ahead
Eli Lilly Is The Nvidia Of Weight Loss And GLP-1 Space, Says Roundhill Investments CEO, Emphasizes Market Leadership And Growth Potential Of Zepbound Maker
Chinese E-Commerce Giant Drops 35% In 2 Days, But Analysts See 92% Upside Potential
Eli Lilly's Alzheimer's Drug Faces UK Agency Block After Biogen's Medicine Rejection Over Cost, Safety
Eli Lilly’s Alzheimer’s Drug Could be Rejected by NHS